Pre-Exposure Prophylaxis

The annual incidence of HIV in the United States declined 73% from a peak of 130,400 infections in 1984 and 1985 to 34,800 infections in 2019, according to estimates published today in MMWR.

The CDC released a draft of revised clinical practice guidelines for HIV PrEP and took feedback from clinicians via two webinars held May 24 and 25.

ViiV Healthcare said Tuesday that it has initiated a rolling submission of a new drug application for long-acting injectable cabotegravir for HIV PrEP.

Marginalization and stigma are directly related to poor physical and mental health outcomes, according to a speaker at the ACP Internal Medicine Meeting, held virtually.

Gilead Sciences and Merck announced a partnership to codevelop lenacapavir and islatravir as a long-acting two-drug regimen for patients with HIV.

In a trial assessing cabotegravir for HIV PrEP, the long-acting injectable appeared to delay the detection of a small number of incident HIV infections using standard HIV testing, researchers reported.

The CDC’s Advisory Committee on Immunization Practices voted Wednesday to shorten the recommendation for rabies PrEP to a two-dose vaccine schedule, aligning with international guidance.

The target to end the 40-year HIV/AIDS epidemic in the United States is 2030. However, the persistent threat of HIV/AIDS amid ongoing stigma has cast doubt that 2030 is a realistic goal.

According to the CDC, in 2018, Black people accounted for 13% of the United States population and 42% of the country’s new HIV diagnoses.

A once-monthly pill showed promise for HIV PrEP in a phase 2a trial, according to an interim analysis of the data.